Anavex Life Sciences Corp (AVXL)

[Millstone]

I must disagree for the following reasons:

Strong 6: I'm not aware of any AZ patient in recorded trial history improving 4-6 points on an MMSE score after 57 weeks. I'd like to see evidence. Show us what you have. Small study or not, 'cherry picked data' implies that 4-6 point improvement in MMSE is in the realm of possibility after 57 weeks. I have not seen it. If even ONE person improved that much after this time period, it would be a remarkable occurrence, would it not? Let me guess, they didn't really have AZ?

As far as P300 data, when amplitude returns to normal levels after about 57 weeks, this is a clear sign of physiological activity and cannot be ascribed to placebo affect. Baseline to 57 weeks show a clear normalization. Dropouts cannot account for that since baseline was below normal.

Skepticism is always healthy - there are plenty on this board who follow and invest in Anavex. But some of your questions such as 'what makes A2-73 different from another S-1 agonist?' come across as pretty silly.

Do you think 10 cups of coffee would provide similar readouts to A2-73 like our 'doctor' friend who abandoned AZ research and now builds websites for people at 9/Euros per hour?